CL2004001702A1 - Uso de compuestos de formula definida que son antagonistas del receptor v1a de la vasopresina para preparar un medicamento util en el tratamiento de la eyaculacion prematura o eyaculacion rapida. - Google Patents

Uso de compuestos de formula definida que son antagonistas del receptor v1a de la vasopresina para preparar un medicamento util en el tratamiento de la eyaculacion prematura o eyaculacion rapida.

Info

Publication number
CL2004001702A1
CL2004001702A1 CL200401702A CL2004001702A CL2004001702A1 CL 2004001702 A1 CL2004001702 A1 CL 2004001702A1 CL 200401702 A CL200401702 A CL 200401702A CL 2004001702 A CL2004001702 A CL 2004001702A CL 2004001702 A1 CL2004001702 A1 CL 2004001702A1
Authority
CL
Chile
Prior art keywords
ejaculation
treatment
antagonists
receptor
vasopresine
Prior art date
Application number
CL200401702A
Other languages
English (en)
Inventor
Peter Wayman Rache Christopher
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CL2004001702A1 publication Critical patent/CL2004001702A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

LA INVENCION SE REFIERE A UN ENVASE O CAJA ADECUADO PARA COLOCAR UN MEDIO DE INFORMACION/MUSICA TIPO DISCO, QUE COMPRENDE UNA BASE CON UNA SUPERFICIE BASAL PLANA, UNA TAPA O CUBIERTA, UN LOMO QUE INTERCONECTA LA BASE CON LA CUBIERTA. UNA FORMACION RODEADORA SE EXTIENDE DESDE LA SUPERFICIE BASAL PLANA, FORMANDO UNA PARED VERTICAL CIRCULAR. DICHA FORMACION TIENE UNA PRIMERA SUPERFICIE DE CONEXION SOPORTANTE Y UNA SEGUNDA SUPERFICIE DE CONEXION SOPORTANTE, SEPARANDO UNA ABERTURA DICHAS SUPERFICIES DE CONEXION SOPORTANTES PRIMERA Y SEGUNDA. SE DISPON
CL200401702A 2003-07-23 2004-07-06 Uso de compuestos de formula definida que son antagonistas del receptor v1a de la vasopresina para preparar un medicamento util en el tratamiento de la eyaculacion prematura o eyaculacion rapida. CL2004001702A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0317227.7A GB0317227D0 (en) 2003-07-23 2003-07-23 Treatment of male sexual dysfunction

Publications (1)

Publication Number Publication Date
CL2004001702A1 true CL2004001702A1 (es) 2005-05-13

Family

ID=27772516

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200401702A CL2004001702A1 (es) 2003-07-23 2004-07-06 Uso de compuestos de formula definida que son antagonistas del receptor v1a de la vasopresina para preparar un medicamento util en el tratamiento de la eyaculacion prematura o eyaculacion rapida.

Country Status (12)

Country Link
EP (1) EP1656183B1 (es)
JP (1) JP2006528171A (es)
AT (1) ATE380048T1 (es)
BR (1) BRPI0412255A (es)
CA (1) CA2533177A1 (es)
CL (1) CL2004001702A1 (es)
GB (1) GB0317227D0 (es)
MX (1) MXPA05014200A (es)
TW (1) TW200510424A (es)
UA (1) UA79674C2 (es)
WO (1) WO2005006899A1 (es)
ZA (1) ZA200505957B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1663978B1 (en) 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
GB0504556D0 (en) * 2005-03-04 2005-04-13 Pfizer Ltd Novel pharmaceuticals
EP1863795B1 (en) * 2005-03-21 2008-10-29 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
US20220152032A1 (en) * 2020-11-13 2022-05-19 Pharma America Holding Inc. Sexual therapy formulation and method of treatment
CN117414361A (zh) * 2023-09-28 2024-01-19 华中农业大学 一种化合物在预防和治疗革兰氏阴性菌病方面的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058880A1 (en) * 2000-02-08 2001-08-16 Yamanouchi Pharmaceutical Co., Ltd. Novel triazole derivatives
GB0224919D0 (en) * 2002-10-25 2002-12-04 Pfizer Ltd Triazole compounds useful in therapy

Also Published As

Publication number Publication date
ATE380048T1 (de) 2007-12-15
EP1656183B1 (en) 2007-12-05
TW200510424A (en) 2005-03-16
CA2533177A1 (en) 2005-01-27
MXPA05014200A (es) 2006-07-03
GB0317227D0 (en) 2003-08-27
ZA200505957B (en) 2006-11-29
UA79674C2 (en) 2007-07-10
EP1656183A1 (en) 2006-05-17
JP2006528171A (ja) 2006-12-14
WO2005006899A1 (en) 2005-01-27
BRPI0412255A (pt) 2006-09-19

Similar Documents

Publication Publication Date Title
CO6361994A2 (es) Antagonistas del receptor de orexina de isonicotinamida
CO6410295A2 (es) Derivados de indol como antagonistas del receptor crth2
EA200901099A1 (ru) Соединения и способы модулирования сопряженных с g-белком рецепторов
MX2009005461A (es) N-oxidos de analogos de 4,5-epoxi-morfinano.
CR9644A (es) Agonistas del receptor de la hormonatiroidea
CO6351782A2 (es) COMPUESTOS NOVEDOSOS CON ACTIVIDAD ANTAGONISTA DEL RECEPTOR á 7 NICOTINICO DE ACETILCOLINA
UY28766A1 (es) Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico
MXPA03007513A (es) Compuestos heteropoliciclicos y su uso como antagonistas del receptor metabotropico de glutamato.
BRPI0414592A (pt) antagonistas de receptores de trombina
ATE469895T1 (de) Cgrp-rezeptorantagonisten
CR9291A (es) Anticuerpos para interleucina-17f y otros antagonistas de la senalizacion de il-17f, y sus usos
UY28775A1 (es) Tetrahidroquinolinonas y su uso como antagonistas de receptores de glutamato metabotropico
ECSP034898A (es) 2,5-DIARILPIRAZINAS, 2,5-DIARILPIRIDINAS y 2,5- DIARILPIRIMIDINAS
ECSP055599A (es) AGONISMO DEL RECEPTOR DE 5HT2a PARA EL TRATAMIENTO DE DISFUNCION TERMORREGULADORA
MA32537B1 (fr) Dérivés de pyrazolo [5,1-b] oxazole en tant qu'antagonistes de crf1
SV2005002061A (es) Derivados de piridilo y su uso como antagonistas del receptor mglu5 ref. x-16538
UY28852A1 (es) Nuevos compuestos con estructura de alquino con acción antagonista de mch y medicamentos que contienen estos compuestos
CO2023007404A2 (es) Compuestos y su uso en el tratamiento de trastornos mediados por receptores de taquicinina
EA200702062A1 (ru) Пиримидиндионовые производные как антагонисты прокинетициновых рецепторов
EA200700365A1 (ru) Производные индол-2-карбоксамидина как антагонисты nmda рецептора
CL2004001702A1 (es) Uso de compuestos de formula definida que son antagonistas del receptor v1a de la vasopresina para preparar un medicamento util en el tratamiento de la eyaculacion prematura o eyaculacion rapida.
ECSP088878A (es) Proceso para la preparación de indazolil ureas que inhiben receptores de vanilloides del subtipo 1 (vr1)
GB2470495A (en) Oxazolidine derivatives as NMDA antagonists
AR073708A1 (es) Compuestos intermediarios de tiazolil -pirazolopirimidina y procesos sinteticos que los incluyen
MX2007004661A (es) Derivados de 1-(hetero)aril-3-amino-pirrolidina para usarse como antagonistas del receptor mglur3.